Welcome to our dedicated page for Aspira Womens Health SEC filings (Ticker: AWHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aspira Women's Health Inc. (AWHL) SEC filings page on Stock Titan brings together the company’s official regulatory documents, offering a detailed view of its operations, capital structure, and risk profile. Aspira is a smaller reporting company in the diagnostics and research segment of healthcare, focused on noninvasive, AI-powered tests for gynecologic diseases such as ovarian cancer and endometriosis.
Through registration statements on Form S-1 and S-1/A, Aspira outlines its business model, including its OvaSuite℠ portfolio of ovarian cancer risk assessment tests (OvaWatch® and Ova1Plus®), its CLIA laboratory operations, and its development pipeline for the ENDOinform™ endometriosis test. These filings also describe the company’s plans to commercialize its technology, its use of multi-omics biomarkers and AI algorithms, and its status as a non-accelerated filer and smaller reporting company.
Investors can review Form 8-K current reports for material events such as private placements of convertible notes and warrants, equity purchase agreements, laboratory services agreements, listing changes from OTCQB to OTCQX, and updates on government-funded programs. Filings detailing purchase agreements with institutional investors and equity line arrangements provide insight into how Aspira raises capital to support its commercial and R&D activities.
On this page, Stock Titan pairs real-time updates from EDGAR with AI-powered summaries that help explain complex sections of Aspira’s filings. Users can quickly understand key elements of annual and quarterly reports when available, including product revenue composition, operating expense trends, and liquidity discussions, as disclosed in the company’s financial statements. Form 4 insider transaction reports, when filed, can be accessed to see how directors and officers transact in AWHL shares.
Use this SEC filings hub to navigate Aspira’s S-1 and S-1/A registration statements, 8-K and 8-K/A current reports, and other disclosures. The AI-generated overviews are designed to highlight important terms, financing structures, and business descriptions so that readers can more efficiently interpret Aspira Women’s Health Inc.’s regulatory record.
Aspira Women's Health Inc. director Cynthia Hundorfean reported receiving a stock option grant. On 12/02/2025, she was granted options to buy 238,085 shares of Aspira common stock at an exercise price of $0.35 per share. These options become exercisable on 12/02/2025 and expire on 12/02/2035. Following this grant, she beneficially owns 238,085 derivative securities directly.
Aspira Women's Health Inc. reported an insider equity award for one of its directors. On 12/02/2025, the reporting person received a stock option, described as a right to buy up to 314,811 shares of the company’s common stock at an exercise price of $0.35 per share. The option becomes exercisable on the same date, 12/02/2025, and is scheduled to expire on 12/02/2035.
Following this grant, the reporting person beneficially owns 314,811 derivative securities directly in the form of this stock option. The form is signed by /s/ John D. Fraser, indicating his role as the reporting person and confirming the director status in relation to Aspira Women's Health.
Aspira Women's Health Inc. director reports new stock option grant. A director of Aspira Women's Health Inc. received a stock option on 12/02/2025 covering 135,592 shares of common stock. The option has an exercise price of $0.35 per share, is listed as exercisable on 12/02/2025, and expires on 12/02/2035. After this transaction, the director beneficially owns 135,592 derivative securities, held directly.
Aspira Women's Health Inc. reported an insider equity award for director Winfred Parnell. On 12/02/2025, Parnell received a stock option to buy 185,178 shares of common stock at an exercise price of $0.35 per share. The option becomes exercisable on 12/02/2025 and expires on 12/02/2035. After this award, Parnell beneficially owned 185,178 derivative securities directly.
Aspira Women's Health Inc. director Jeffrey Cohen reported a new stock option grant. On 12/02/2025, he received an option to buy 213,518 shares of Aspira Women's Health common stock at an exercise price of $0.35 per share. The option is exercisable starting on the grant date and expires on 12/02/2035. After this grant, Cohen beneficially owns 213,518 derivative securities directly in the form of this stock option, giving him potential future ownership if he chooses to exercise.
Aspira Women's Health Inc. reported an insider equity award for a director. A Form 4 filing shows that on 12/02/2025 a director received a stock option (right to buy) covering 198,097 shares of Aspira Women's Health common stock at an exercise price of $0.35 per share. The option becomes exercisable on 12/02/2025 and expires on 12/02/2035. Following this grant, the director beneficially owns 198,097 derivative securities, held in direct ownership form.
Aspira Women’s Health Inc. reported Q3 2025 results. Revenue was $2,305,000, with gross profit of $1,383,000. Operating expenses were $2,962,000, leading to a loss from operations of $1,579,000. A non-cash loss from the change in fair value of warrant liabilities of $4,309,000 drove total other (expense) income, net to $(3,313,000), and the company recorded a net loss of $4,892,000 for the quarter.
For the nine months ended September 30, 2025, revenue was $6,988,000 and net loss was $9,411,000. Cash and cash equivalents were $3,809,000, working capital was $1,626,000, and long-term debt (DECD loan) was $1,100,000. Warrant liabilities increased to $5,280,000, largely tied to March 2025 warrants measured at fair value. Financing during 2025 included $3,484,000 in gross proceeds under the 2024 at-the-market program and $2,949,000 in gross proceeds from a September 2025 private placement.
The company disclosed substantial doubt about its ability to continue as a going concern within one year. Its common stock was delisted from Nasdaq in April 2025 and began trading on the OTC QX Best Market on October 14, 2025.
Aspira Women’s Health Inc. filed a Form 8-K announcing it issued a press release reporting financial results for the three and nine months ended September 30, 2025. The press release is provided as Exhibit 99.1.
The filing lists the company’s common stock trading on the OTC QX Market under the symbol AWHL.
Aspira Women’s Health Inc. filed an amended Form 8-K to correct the form of its Amended and Restated Series A Common Stock Warrant. The company stated that the version previously included with its September 25, 2025 disclosure inadvertently listed an incorrect termination date. The corrected warrant form is filed as Exhibit 4.1 and incorporated by reference.
The amendment is reported under Item 1.01 (Entry into a Material Definitive Agreement), with Item 3.02 (Unregistered Sales of Equity Securities) incorporating Item 1.01 by reference. The earliest event date is September 19, 2025.